TapewireFind a company

person · Reporting owner

AUBERTON-HERVE ANDRE-JACQUES

Disclosed activity across 2 companies

Tapewire entity
95840
SEC CIK
0001730329

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Bionik Laboratories Corp.BNKL · Entity 112055DirectorJune 13, 2023June 21, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bionik Laboratories Corp.

Report date June 13, 2023 · Filed June 21, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectShares held through Star SCI1,109,271 Reported balance After 2023-06-13 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2023-06-13 · Conversion · Acquired 186,111 · Balance 1,109,271

F1: Effective as of June 13, 2023, approximately $310,185 of principal and accrued interest of a convertible promissory note issued to Star SCI, an affiliate of the reporting person, converted in accordance with its terms into 186,111 shares of the Issuer's common stock

Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2024-06-01IndirectThrough Star SCI1 Reported balance After 2023-06-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-06-13 · Purchase · Acquired 1 · Balance 1

F2: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share.

Common StockSEC Table I · non-derivativeIndirectShares held through 4A Consulting and Engineering10,693 Reported balance Holding disclosure · report date 2023-06-13 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 10,693

Common StockSEC Table I · non-derivativeDirect95,149 Reported balance Holding disclosure · report date 2023-06-13 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 95,149

Filing footnotes · ownership attribution and instrument terms

F1: Effective as of June 13, 2023, approximately $310,185 of principal and accrued interest of a convertible promissory note issued to Star SCI, an affiliate of the reporting person, converted in accordance with its terms into 186,111 shares of the Issuer's common stock

F2: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MOBIX LABS, INC

Report date December 21, 2023 · Filed December 26, 2023

Section 16 reporting ended · disclosed 2023-12-26. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeIndirectSee footnote342,917 Reported balance After 2023-12-21 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2023-12-21 · Grant · Acquired 145,335 · Balance 342,917

F1: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."

F2: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.

F3: Includes an additional 197,582 shares of Class A Common Stock that may be deemed to be indirectly owned by the Reporting Person through his direct and indirect ownership interests in Sponsor, which shares are expected to be distributed to the Reporting Person over time. In addition, the Reporting Person holds private placement warrants, exercisable to purchase shares of Class A Common Stock of the Issuer at an exercise price of $11.50 per share, subject to certain adjustments, which he received in a pro rata distribution from the Sponsor on December 21, 2023.

F4: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Class A Common StockSEC Table I · non-derivativeIndirectSee footnote540,966 Reported balance After 2023-12-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2023-12-21 · Grant · Acquired 198,049 · Balance 540,966

F1: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."

F2: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.

F4: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Make-Whole Shares (right to acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00IndirectSee footnote145,335 Reported balance After 2023-12-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-12-21 · Grant · Acquired 145,335 · Balance 145,335

F5: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

F2: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.

F1: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."

F4: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Class A Common StockSEC Table I · non-derivativeDirect27,826 Reported balance Holding disclosure · report date 2023-12-21 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 27,826

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."

F2: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.

F3: Includes an additional 197,582 shares of Class A Common Stock that may be deemed to be indirectly owned by the Reporting Person through his direct and indirect ownership interests in Sponsor, which shares are expected to be distributed to the Reporting Person over time. In addition, the Reporting Person holds private placement warrants, exercisable to purchase shares of Class A Common Stock of the Issuer at an exercise price of $11.50 per share, subject to certain adjustments, which he received in a pro rata distribution from the Sponsor on December 21, 2023.

F4: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

F5: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 21, 2023 Filed Dec 26, 2023 22:56 UTC MOBIX LABS, INC MOBX · Entity 7651 GrantMake-Whole Shares (right to acquire) · Derivative 145,335 Not disclosed Strike: $10.00 Not disclosed
Disclosure

SEC source: 0001104659-23-129309 · tm2333669-16_4seq1.xml · derivative · entry 4

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 145,335

Underlying: Class A Common Stock · 145,335 shares

Expires not disclosed

F5 · kind: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

F2 · shares: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.

F1 · price: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."

F5 · price: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

F5 · derivative.exercise_date: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

F5 · derivative.expiration_date: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

F2 · derivative.underlying_shares: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.

F5 · derivative.underlying_shares: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

F2 · balance_after: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.

F4 · ownership.nature: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Read SEC document
December 21, 2023 Filed Dec 26, 2023 22:56 UTC MOBIX LABS, INC MOBX · Entity 7651 GrantClass A Common Stock 198,049 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-23-129309 · tm2333669-16_4seq1.xml · nonDerivative · entry 2

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 540,966

F1 · kind: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."

F2 · shares: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.

F1 · price: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."

F4 · ownership.nature: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Read SEC document
December 21, 2023 Filed Dec 26, 2023 22:56 UTC MOBIX LABS, INC MOBX · Entity 7651 GrantClass A Common Stock 145,335 $10.00 $1,453,350.00
Disclosure

SEC source: 0001104659-23-129309 · tm2333669-16_4seq1.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 342,917

F1 · kind: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."

F2 · shares: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.

F1 · price: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."

F3 · balance_after: Includes an additional 197,582 shares of Class A Common Stock that may be deemed to be indirectly owned by the Reporting Person through his direct and indirect ownership interests in Sponsor, which shares are expected to be distributed to the Reporting Person over time. In addition, the Reporting Person holds private placement warrants, exercisable to purchase shares of Class A Common Stock of the Issuer at an exercise price of $11.50 per share, subject to certain adjustments, which he received in a pro rata distribution from the Sponsor on December 21, 2023.

F4 · ownership.nature: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Read SEC document
June 13, 2023 Filed Jun 21, 2023 10:58 UTC Bionik Laboratories Corp. BNKL · Entity 112055 PurchaseConvertible Promissory Note · Derivative 1 $220,000.00 Strike: $0.60 $220,000.00
Disclosure

SEC source: 0001104659-23-073231 · tm2319148-4_4seq1.xml · derivative · entry 4

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Through Star SCI

Disclosed balance after: 1

Underlying: Common Stock, par value $0.001 per share · 366,667 shares

Expires 2024-06-01

F2 · derivative.exercise_price: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share.

F2 · derivative.exercise_date: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share.

F2 · derivative.expiration_date: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share.

F2 · derivative.underlying_shares: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share.

Read SEC document
June 13, 2023 Filed Jun 21, 2023 10:58 UTC Bionik Laboratories Corp. BNKL · Entity 112055 ConversionCommon Stock 186,111 $0.60 $111,666.60
Disclosure

SEC source: 0001104659-23-073231 · tm2319148-4_4seq1.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held through Star SCI

Disclosed balance after: 1,109,271

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Effective as of June 13, 2023, approximately $310,185 of principal and accrued interest of a convertible promissory note issued to Star SCI, an affiliate of the reporting person, converted in accordance with its terms into 186,111 shares of the Issuer's common stock

Read SEC document
June 09, 2023 Filed Jun 21, 2023 10:55 UTC Bionik Laboratories Corp. BNKL · Entity 112055 PurchaseCommon Stock 650,000 $0.60 $390,000.00
Disclosure

SEC source: 0001104659-23-073228 · tm2319148-5_4seq1.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held through Star SCI

Disclosed balance after: 923,160

F1 · price: The reporting person acquired the shares of common stock in lieu of cash payment of an aggregate of $390,000 in accrued and unpaid fees relating to reporting person's services as Chairman of the Board of the Issuer.

Read SEC document
February 24, 2022 Filed Feb 28, 2022 16:38 UTC MOBIX LABS, INC CLAY · Entity 7651 Disposition to issuerOrdinary Shares 4,174 $0.00 $0.00
Disclosure

SEC source: 0001104659-22-027820 · tm227631-1_4seq1.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,826

F1 · shares: The ordinary shares are described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-257459) (the "Registration Statement") and have no expiration date. On February 24, 2022, the Reporting Person transferred 4,174 ordinary shares to Chavant Capital Partners LLC, the sponsor of the Issuer, for no consideration.

F1 · price: The ordinary shares are described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-257459) (the "Registration Statement") and have no expiration date. On February 24, 2022, the Reporting Person transferred 4,174 ordinary shares to Chavant Capital Partners LLC, the sponsor of the Issuer, for no consideration.

Read SEC document
July 15, 2021 Filed Jun 21, 2022 17:49 UTC Bionik Laboratories Corp. BNKL · Entity 112055 Exercise / conversionStock Option (right to buy) · Derivative 7,500 $0.00 Strike: $3.16 $0.00
Disclosure

SEC source: 0001104659-22-073086 · tm2218715-2_4seq1.xml · derivative · entry 5

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 7,500 shares

Expires 2026-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the reporting person.

F2 · derivative.exercise_date: The options vest 2,500 on May 31, 2019, 2,500 on November 30, 2019 and 2,500 on May 31, 2020.

Read SEC document
July 15, 2021 Filed Jun 21, 2022 17:49 UTC Bionik Laboratories Corp. BNKL · Entity 112055 Exercise / conversionStock Option (right to buy) · Derivative 51,878 $0.00 Strike: $3.60 $0.00
Disclosure

SEC source: 0001104659-22-073086 · tm2218715-2_4seq1.xml · derivative · entry 4

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,881

Underlying: Common Stock, par value $0.001 per share · 51,878 shares

Expires 2026-07-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the reporting person.

Read SEC document
July 15, 2021 Filed Jun 21, 2022 17:49 UTC Bionik Laboratories Corp. BNKL · Entity 112055 Exercise / conversionCommon Stock, par value $0.001 per share 7,500 $3.16 $23,700.00
Disclosure

SEC source: 0001104659-22-073086 · tm2218715-2_4seq1.xml · nonDerivative · entry 2

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held through Star SCI or 4A Consulting and Engineering

Disclosed balance after: 283,853

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the reporting person.

Read SEC document
July 15, 2021 Filed Jun 21, 2022 17:49 UTC Bionik Laboratories Corp. BNKL · Entity 112055 Exercise / conversionCommon Stock, par value $0.001 per share 51,878 $3.60 $186,501.41
Disclosure

SEC source: 0001104659-22-073086 · tm2218715-2_4seq1.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held through Star SCI or 4A Consulting and Engineering

Disclosed balance after: 276,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the reporting person.

Read SEC document
March 26, 2021 Filed Apr 1, 2021 12:22 UTC Bionik Laboratories Corp. BNKL · Entity 112055 PurchaseCommon Stock, par value $0.001 per share 95,149 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-045413 · tm2111532-2_4seq1.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director · Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,149

F1 · price: The reporting person acquired the shares of common stock in lieu of cash payment for an aggregate of $255,000 in accrued and unpaid fees relating to reporting person's services as a director of the Issuer.

Read SEC document
July 26, 2019 Filed Aug 8, 2019 15:50 UTC Bionik Laboratories Corp. BNKL · Entity 112055 GrantEmployee Stock Option (right to buy) · Derivative 115,759 $0.00 Strike: $3.59 $0.00
Disclosure

SEC source: 0001144204-19-038541 · tv526242_4.xml · derivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,759

Underlying: Common Stock, par value $0.001 · 115,759 shares

Expires 2026-07-26

F1 · derivative.exercise_date: The option shall be fully vested on the occurrence of any of the following conditions: (a) A Change of Control (as defined in the Company's 2014 Equity Incentive Plan) or (b) upon the Reporting Person not being Chairman of the Board of the Issuer for any reason.

Read SEC document
May 31, 2019 Filed Jun 4, 2019 15:57 UTC Bionik Laboratories Corp. BNKL · Entity 112055 GrantEmployee Stock Option (right to buy) · Derivative 7,500 $0.00 Strike: $3.16 $0.00
Disclosure

SEC source: 0001144204-19-029709 · tv523059_4.xml · derivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director · Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock, par value $0.001 · 7,500 shares

Expires 2026-05-31

F1 · derivative.exercise_date: The options vest 2,500 on May 31, 2019, 2,500 on November 30, 2019 and 2,500 on May 31, 2020.

Read SEC document
March 28, 2019 Filed Apr 9, 2019 18:42 UTC Bionik Laboratories Corp. BNKL · Entity 112055 ConversionCommon Stock 81,492 $3.89 $316,800.15
Disclosure

SEC source: 0001144204-19-018936 · tv518554_4.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held through Star SCI and 4A Consulting & Engineering

Disclosed balance after: 224,475

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: Effective as of March 28, 2019, an aggregate amount of $316,800 of principal and accrued interest in convertible promissory notes issued to Star SCI (the "Notes") converted in accordance with their terms into 81,492 shares of the Issuer's common stock.

F2 · shares: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before March 28, 2019.

F2 · price: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before March 28, 2019.

Read SEC document
July 24, 2018 Filed Jul 26, 2018 13:55 UTC Bionik Laboratories Corp. BNKL · Entity 112055 ConversionCommon Stock 6,688,480 $0.05 $343,119.02
Disclosure

SEC source: 0001144204-18-040074 · tv499375_4.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held through Star SCI and 4A Consulting & Engineering

Disclosed balance after: 21,447,183

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: Effective as of July 20, 2018, an aggregate amount of $308,807 in convertible promissory notes issued to Star SCI (the "Notes") converted in accordance with their terms into 6,688,480 shares of the Issuer's common stock. For purposes of the filing of this Form 4, the transaction date is deemed to be July 24, 2018, as that was the date that the Issuer preliminarily determined the number of shares of common stock that the Notes were convertible into in accordance with the terms of the Notes.

F2 · shares: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before July 20, 2018. As of the date hereof, the Issuer has not definitively determined the conversion price. In the event that the Issuer definitively determines that the conversion price was lower than $0.0513, the Reporting Person will file an amendment to this Form 4 to reflect the correct conversion price, number of shares acquired upon conversion, and the amount of securities beneficially owned following the reported transaction.

F2 · price: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before July 20, 2018. As of the date hereof, the Issuer has not definitively determined the conversion price. In the event that the Issuer definitively determines that the conversion price was lower than $0.0513, the Reporting Person will file an amendment to this Form 4 to reflect the correct conversion price, number of shares acquired upon conversion, and the amount of securities beneficially owned following the reported transaction.

F2 · balance_after: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before July 20, 2018. As of the date hereof, the Issuer has not definitively determined the conversion price. In the event that the Issuer definitively determines that the conversion price was lower than $0.0513, the Reporting Person will file an amendment to this Form 4 to reflect the correct conversion price, number of shares acquired upon conversion, and the amount of securities beneficially owned following the reported transaction.

Read SEC document
June 13, 2018 Filed Jun 15, 2018 14:39 UTC Bionik Laboratories Corp. BNKL · Entity 112055 ConversionCommon Stock 1,039,115 $0.06 $64,944.69
Disclosure

SEC source: 0001144204-18-034393 · tv496575_4.xml · nonDerivative · entry 2

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held through 4A Consulting and Engineering

Disclosed balance after: 14,758,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: As previously disclosed by the reporting person on a Form 4, filed with the Securities and Exchange Commission on April 3, 2018, as of March 31, 2018, the Issuer became obligated to issue 1,039,115 shares of common stock (the "4A Shares") to 4A Consulting and Engineering, an affiliate of the reporting person, as a result of the conversion of certain outstanding convertible promissory notes in accordance with their terms. The reporting person is filing this Form 4 to disclose that the Issuer issued the 4A Shares as of June 13, 2018.

Read SEC document
June 13, 2018 Filed Jun 15, 2018 14:39 UTC Bionik Laboratories Corp. BNKL · Entity 112055 ConversionCommon Stock 1,040,152 $0.06 $65,009.50
Disclosure

SEC source: 0001144204-18-034393 · tv496575_4.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held through Star SCI

Disclosed balance after: 14,758,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: As previously disclosed by the reporting person on a Form 4, filed with the Securities and Exchange Commission on April 3, 2018, as of March 31, 2018, the Issuer became obligated to issue 1,010,152 shares of common stock (the "Star Shares") to Star SCI, an affiliate of the reporting person, as a result of the conversion of certain outstanding convertible promissory notes in accordance with their terms. The reporting person is filing this Form 4 to disclose that the Issuer issued the Star Shares as of June 13, 2018.

Read SEC document
March 31, 2018 Filed Apr 3, 2018 19:26 UTC Bionik Laboratories Corp. BNKL · Entity 112055 ConversionCommon Stock 564,726 $0.06 $35,295.38
Disclosure

SEC source: 0001144204-18-019057 · tv490253_4.xml · nonDerivative · entry 2

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held through 4A Consulting and Engineering

Disclosed balance after: 12,679,436

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: On March 31, 2018, an aggregate amount of $100,200 in convertible promissory notes converted in accordance with their terms into (i) 564,726 shares of the Issuer's common stock, and (ii) 1,039,115 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.

Read SEC document
March 31, 2018 Filed Apr 3, 2018 19:26 UTC Bionik Laboratories Corp. BNKL · Entity 112055 ConversionCommon Stock 12,114,710 $0.06 $757,169.38
Disclosure

SEC source: 0001144204-18-019057 · tv490253_4.xml · nonDerivative · entry 1

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held through Star SCI

Disclosed balance after: 12,679,436

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On March 31, 2018, an aggregate amount of $821,850 in convertible promissory notes converted in accordance with their terms into (i) 12,114,710 shares of the Issuer's common stock, and (ii) 1,040,152 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.

Read SEC document
August 14, 2017 Filed Apr 3, 2018 19:26 UTC Bionik Laboratories Corp. BNKL · Entity 112055 GrantWarrant · Derivative 1,600,640 $0.00 Strike: $0.06 $0.00
Disclosure

SEC source: 0001144204-18-019057 · tv490253_4.xml · derivative · entry 3

AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Warrants held through held through Star SCI

Disclosed balance after: 1,600,640

Underlying: Common Stock · 1,600,640 shares

Expires 2022-08-14

F3 · date: As of the transaction date, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018.

F3 · derivative.exercise_date: As of the transaction date, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.